This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Press Releases

ITAC Releases Clinical Practice Guidelines for Treatment and Prophylaxis of VTE in Cancer Patients

Wednesday, September 4, 2019  
Share |

First guidelines to provide evidence-based guidance on the use of direct oral anticoagulants in cancer patients

The International Initiative on Thrombosis and Cancer (ITAC) announced publication of the 2019 update of their guidelines for the treatment and prophylaxis of cancer-associated thrombosis (CAT) in The Lancet Oncology

The International Society on Thrombosis and Haemostasis (ISTH) has reviewed and endorsed the methodology used in creating these 2019 guidelines.

The 2019 update of the ITAC-CME clinical practice guidelines marks a shift in how physicians and allied healthcare professionals will manage the treatment and prophylaxis of CAT. Since publication of the last iteration of the guidelines in 2016, several head-to-head clinical trials have compared the safety and efficacy of the direct oral anticoagulants against low-molecular-weight heparin, the treatment standard for the prevention and treatment of CAT. The 2019 ITAC guidelines are the first major clinical practice guidelines to incorporate data from these clinical trials. The French National Institute of Cancer (INCa) provided methodological support during development of the guidelines. 

The 2019 ITAC international guidelines were also reviewed by an international advisory committee of 83 experts, comprising hematologists, oncologists, nurses, and patient representatives. Members of the advisory committee are from Europe, North/South America, the Middle East, and Asia, and will contribute actively to the dissemination of the guidelines.

To help implement the guidelines into practice, ITAC has updated a user-friendly, point-of-care, decision support free interactive mobile app (“International VTE and Cancer Guidelines”), which is available from the iOS App Store, Google Play, and online. The app will be launched in the coming weeks.

About ITAC
The International Initiative on Cancer and Thrombosis (ITAC) is a non-profit multidisciplinary group of academic experts from across the globe committed to improving the management of patients with cancer-associated thrombosis (CAT). This mission is accomplished through the development of evidence-based clinical practice guidelines and educational programs that disseminate these updated recommendations to physicians, nurses, and other allied health professionals. The overarching goal of the initiative is to improve the lives and health outcomes of cancer patients worldwide, and to help reduce the economic burden related to CAT on healthcare systems.

Corresponding Authors
Professor Dominique Farge (ITAC chair),
Hôpital St-Louis, AP-HP, 1 avenue Claude Vellefaux, Université de Paris, France
Department of Internal Medicine, McGill University, Montréal, Canada
dominique.farge-bancel@aphp.fr; dominique.farge@mcgill.ca

Professor Jim Douketis (ITAC chair),
Department of Medicine, McMaster University, Hamilton, Canada.
jdouket@mcmaster.ca


Membership Management Software Powered by YourMembership  ::  Legal